---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000241"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:54:59.193527+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunic reports FY2022 net loss of $120.4M; cash $116.4M; goodwill impairment $33M

## Summary
- Net loss $120.4M ($3.78/share) vs $92.9M ($3.93/share) in 2021; R&D expenses $71.3M.
- Recorded non-cash goodwill impairment of $33M in Q4 2022 due to stock price decline after izumerogant psoriasis data.
- Cash, equivalents and investments $116.4M as of Dec 31, 2022; expected to fund operations into Q4 2024.
- Clinical milestones: IMU-856 celiac data mid-2023; CALLIPER progressive MS interim H2 2023; ENSURE relapsing MS interim late 2024.
- Closed $60M private placement in Oct 2022 with new and existing institutional investors.

## SEC filing metadata
- accession: 0001193805-23-000241
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/0001193805-23-000241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/e618296_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000241
- JSON: https://secwatch.observer/filing/0001193805-23-000241.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000241.txt

## Key facts
- Earnings Releases
  IMMUNIC, INC. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 23, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter and year ended December 31, 2022 and providing a corporate update (the “Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/0001193805-23-000241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.